- Home
- HMST vs ZURA Comparison
HMST vs ZURA Comparison
Compare HMST & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- ZURA
- Stock Information
- Founded
- HMST 1921
- ZURA 2022
- Country
- HMST United States
- ZURA United States
- Employees
- HMST N/A
- ZURA N/A
- Industry
- HMST Major Banks
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HMST Finance
- ZURA Health Care
- Exchange
- HMST Nasdaq
- ZURA Nasdaq
- Market Cap
- HMST 246.0M
- ZURA 69.9M
- IPO Year
- HMST 2012
- ZURA N/A
- Fundamental
- Price
- HMST $13.14
- ZURA $1.05
- Analyst Decision
- HMST Hold
- ZURA Buy
- Analyst Count
- HMST 3
- ZURA 7
- Target Price
- HMST $14.17
- ZURA $14.33
- AVG Volume (30 Days)
- HMST 66.7K
- ZURA 755.8K
- Earning Date
- HMST 07-28-2025
- ZURA 08-08-2025
- Dividend Yield
- HMST N/A
- ZURA N/A
- EPS Growth
- HMST N/A
- ZURA N/A
- EPS
- HMST N/A
- ZURA N/A
- Revenue
- HMST $78,454,000.00
- ZURA N/A
- Revenue This Year
- HMST $161.80
- ZURA N/A
- Revenue Next Year
- HMST $8.90
- ZURA N/A
- P/E Ratio
- HMST N/A
- ZURA N/A
- Revenue Growth
- HMST N/A
- ZURA N/A
- 52 Week Low
- HMST $8.41
- ZURA $0.97
- 52 Week High
- HMST $16.10
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- HMST 50.08
- ZURA 48.12
- Support Level
- HMST $12.05
- ZURA $1.10
- Resistance Level
- HMST $12.84
- ZURA $1.22
- Average True Range (ATR)
- HMST 0.34
- ZURA 0.09
- MACD
- HMST -0.08
- ZURA 0.00
- Stochastic Oscillator
- HMST 27.34
- ZURA 31.25
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.